AMSTERDAM, NETHERLANDS--(Marketwire - September 09, 2008) - Clinquest Group of Amsterdam, The Netherlands and TNO of Delft, The Netherlands, expand their existing collaboration on CQ07-001 - a Toll-Like Receptor 3 (TLR3) agonist - to include process development, small-scale manufacturing and purification. TNO expands its process development expertise with mammalian cell culture technologies and is committed to building a supporting infrastructure to broaden its overall biopharmaceutical development services portfolio. CQ07-001, a protein, is a promising candidate targeting auto-immune and inflammatory disorders, most notably Rheumatoid Arthritis and Multiple Sclerosis. The new activities are partly financed through the EZ-cofinancing program, a subsidy awarded by the Dutch Ministry of Economic Affairs, specifically for innovative research.
